Gufic Biosciences Approves Unaudited Financial Results for Quarter Ended Sep 30, 2025
Gufic Biosciences board approves unaudited results for quarter ended September 30, 2025. Standalone net profit: ₹1,493.71 Lakh. Consolidated net profit: ₹1,682.40 Lakh. Investment in Gufic Ireland Limited made on August 25, 2025.
The announcement provides details on the company's financial performance, which is important information for investors. The results show a slight decrease in profit compared to the previous year.
The announcement is about the approval of financial results, which is a routine activity. There is no indication of positive or negative sentiment.
* Gufic Biosciences Limited's Board of Directors approved the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025, during its meeting held on November 14, 2025. * The meeting commenced at 5:00 p.m. and concluded at 06:00 p.m. * Standalone total income for the quarter ended September 30, 2025, was ₹23,250.85 Lakh compared to ₹20,429.37 Lakh for the quarter ended September 30, 2024. * Consolidated total income for the quarter ended September 30, 2025, was ₹23,917.00 Lakh compared to ₹20,429.37 Lakh for the quarter ended September 30, 2024. * Standalone net profit for the quarter ended September 30, 2025, was ₹1,493.71 Lakh compared to ₹2,177.61 Lakh for the quarter ended September 30, 2024. * Consolidated net profit for the quarter ended September 30, 2025, was ₹1,682.40 Lakh compared to ₹2,176.86 Lakh for the quarter ended September 30, 2024. * The company has made an investment in Gufic Ireland Limited by way of initial subscription to its share capital on August 25, 2025.
What to do with a filing like this
Gufic Biosciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gufic Biosciences Limited. Read the original for the full detail.